This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 receptor agonists are prescription medications requiring individual clinician evaluation. Consult a licensed healthcare professional before starting any weight management program. This comparison may include affiliate relationships; financial relationships are disclosed where applicable. Individual responses vary. Last reviewed: May 2026.
By UTCardiothoracicSurgery.com Editorial Team
Quick Answer: The GLP-1 telehealth program market in 2026 has consolidated around a narrower set of compliant providers following the FDA's removal of semaglutide and tirzepatide from shortage lists and the April 30, 2026 proposal to restrict 503B compounding. Key evaluation dimensions are: medication type (compounded vs. FDA-approved), provider oversight structure, pricing transparency, cancellation term accuracy, and pharmacy compliance documentation. No single program is universally optimal — the right fit depends on insurance status, cardiac comorbidities, state availability, and tolerance for regulatory uncertainty.
In This Article
How We Evaluated These GLP-1 Telehealth Programs
This comparison evaluates four GLP-1 telehealth programs with meaningful market presence as of May 2026. Programs were selected based on SERP visibility, patient search volume, and relevance to adults evaluating prescription weight management options with a clinical lens.
Each program was evaluated against the same six dimensions: (1) provider oversight structure and clinical credential requirements; (2) medication options and regulatory status of those medications; (3) pricing transparency and consistency between promotional materials and binding legal documents; (4) cancellation and refund terms per published Terms of Service; (5) patient support infrastructure and ongoing monitoring structure; (6) regulatory compliance framework, including pharmacy type and documentation availability.
No independent product testing was conducted. Information for each program is sourced from published Terms of Service, FAQ pages, offer pages, and publicly accessible program materials as of May 2026. Program details may change; verify directly with each platform before enrolling. This comparison does not guarantee eligibility, prescription access, or pricing for any reader. No rank order is intended in the ordering below — programs are presented alphabetically. This comparison may include affiliate relationships disclosed in the disclaimer above.
The Comparison Framework: Decision Points That Matter
Before evaluating individual programs, the framework for evaluation matters as much as the programs themselves. Two categories of adults are reading this comparison, and the relevant decision points differ for each.
Adults without complex medical histories, not on multiple prescription medications, evaluating compounded GLP-1 telehealth programs primarily on cost and convenience: the decision points are pricing accuracy, cancellation flexibility, pharmacy compliance documentation, and state availability. The regulatory environment risk — that compounded GLP-1 program access could change between enrollment and month three — is relevant to budget planning regardless of which program is selected.
Adults with cardiovascular histories, existing cardiac medications, or complex comorbidities: the decision points above still apply, but the primary recommendation is a cardiologist or managing physician conversation before program selection. The clinical coordination requirement is more important than any platform-level pricing difference. Our GLP-1 safety guide for cardiac patients covers the clinical parameters involved.
Calibrate
Calibrate is a telehealth metabolic health program that, as of 2025-2026, shifted its model from compounded GLP-1 medications toward branded FDA-approved options — Wegovy and Zepbound — in response to the FDA regulatory shift. The program has emphasized lifestyle coaching integration alongside prescription access, with a physician-led review model. Published pricing has been higher than compounded alternatives, reflecting branded medication costs, but access to FDA-approved products with manufacturer savings programs changes the effective cost calculation for eligible patients. State availability and insurance navigation support are among the differentiating factors cited by patients who have evaluated Calibrate against compounded alternatives. Cancellation and commitment terms should be verified directly on the current platform before enrolling; program terms have evolved alongside the regulatory landscape.
Found
Found is a telehealth weight management platform that offers both GLP-1 prescription access and non-GLP-1 prescription options (including metformin and other non-GLP-1 medications) within a broader metabolic health framework. The program has positioned itself as a longer-term lifestyle and medication management platform rather than a medication-delivery service. Physicians and nurse practitioners conduct evaluations. The program accepts some insurance and has integrated tools for insurance navigation alongside cash-pay access. Pricing for GLP-1 prescription access varies by medication type and insurance status. Patients who want a platform with multiple prescription tool options beyond GLP-1s and longer-term program infrastructure may find Found's framework more comprehensive than medication-only telehealth models. Verify current medication availability, pricing, and Terms of Service directly before enrolling.
Hims and Hers GLP-1
Hims & Hers previously offered compounded semaglutide through telehealth at competitive pricing and with high consumer visibility. In March 2026, following FDA warning letters and a partnership agreement with Novo Nordisk, Hims & Hers agreed to cease most advertising and marketing of compounded GLP-1 alternatives and shift toward branded medications. As of May 2026, the program's GLP-1 offering has transitioned away from the large-scale compounded model that characterized its 2023-2025 positioning. Patients who had been enrolled in Hims compounded GLP-1 programs during the transition period should confirm their current prescription status and medication source directly with the platform. For new enrollees in 2026, verify the current medication type (compounded or branded), pricing, and terms before committing.
Novi International LLC
Novi International LLC is a telehealth platform that connects eligible US adults with independent licensed clinicians for compounded GLP-1 prescription evaluation. As of May 2026, the platform lists compounded semaglutide from $133 per month and compounded tirzepatide from $166 per month under a stated promotional discount. The program includes medication, supplies, free 2-day shipping, coaching, and ongoing clinician access. Named provider credentials are publicly visible on the site.
A verified discrepancy exists between Novi's FAQ (month-to-month cancellation, cancel anytime) and its Terms of Service (3-month minimum, first 3 months billed upfront and non-refundable once medication dispatched). This is a material consumer disclosure. Before enrolling, email [email protected] and request written confirmation of which cancellation structure applies to your enrollment. The ToS is the binding document, not the FAQ. A detailed review of Novi's program, including the full cancellation term analysis and regulatory context, is available in our Novi GLP-1 program review.
Side-by-Side: Six Decision Points
Provider oversight: Found and Calibrate have published information indicating physician involvement in clinical review. Hims & Hers and Novi use licensed nurse practitioners and physicians depending on state and intake. All four require some form of clinician evaluation before prescribing. The depth of that evaluation — and the extent to which the reviewing clinician has access to the patient's full medication list and cardiac history — varies by platform and depends substantially on what the patient provides during intake.
Medication type: Calibrate has moved toward FDA-approved branded medications. Found offers both GLP-1 and non-GLP-1 prescription options. Hims & Hers has shifted away from compounded models. Novi continues to offer compounded semaglutide and tirzepatide as primary options. FDA-approved medications carry a different quality assurance and regulatory standing than compounded versions; see our full analysis in compounded versus FDA-approved GLP-1 medications.
Pricing transparency: Verified pricing for Novi: $133/mo (semaglutide, promotional) and $166/mo (tirzepatide, promotional). Calibrate, Found, and Hims pricing varies by medication type, insurance status, and program tier. Branded medication pricing through NovoCare (Wegovy) runs approximately $349/month self-pay; LillyDirect (Zepbound) runs approximately $299-449/month self-pay.
Cancellation terms: A verified FAQ-to-ToS discrepancy exists for Novi (FAQ says cancel anytime; ToS says 3-month minimum). Calibrate, Found, and Hims terms should be verified directly from current binding documents before enrolling. Program terms evolve; do not rely on FAQ language as a binding commitment.
Regulatory compliance: Calibrate (branded) and Found (mixed) operate within a more settled regulatory framework. Hims has adapted to the enforcement shift. Novi's compounded model continues to operate within the 503A legal pathway; patients should confirm pharmacy compliance framework before enrolling, particularly given the April 30, 2026 FDA proposal.
Patient support: All four programs include some form of ongoing clinical access. Calibrate has emphasized lifestyle coaching integration. Found has integrated tools across multiple medication categories. Hims and Novi include coaching within subscription pricing. Depth and responsiveness of support vary; patient reviews on third-party platforms provide additional data points, though these should be evaluated with awareness that reviews in this category are subject to selection effects.
Which Formula for Which Situation
For adults with established cardiovascular disease or complex cardiac medication regimens: Cardiologist consultation before program selection is the primary recommendation — not a program. Following that consultation, a program with physician-level oversight (not only NP review), access to branded FDA-approved medication, and the ability to coordinate with existing prescribers may be the most appropriate structure. Calibrate or a traditional endocrinology or obesity medicine referral may better serve this profile than a predominantly compounded telehealth model.
For adults seeking lowest cash-pay access to compounded options with tolerance for regulatory uncertainty: Novi's promotional pricing structure at $133/month for compounded semaglutide is among the most competitive in the market, provided the 3-month upfront commitment and non-refundability of dispensed medication is understood and accepted. Confirm cancellation terms in writing before paying. This structure suits adults without complex cardiac histories who have confirmed state availability and are comfortable with the regulatory environment for compounded medications as it currently stands.
For adults who want multiple prescription tool options within a longer-term program framework: Found's multi-medication platform and longer-term infrastructure may suit adults who are uncertain about GLP-1 eligibility or who want a program that does not begin and end with GLP-1 prescription access.
For adults who prefer FDA-approved branded medications within a telehealth model: Calibrate's post-regulatory-shift positioning, or direct use of NovoCare or LillyDirect manufacturer programs, provides access to FDA-approved medications with documented quality assurance. Medicare-eligible adults should note that the GLP-1 Bridge program begins July 2026 at a $50 monthly copay under Part D.
Frequently Asked Questions
Which GLP-1 telehealth program is best for cardiac patients?
Cardiac patients should consult their cardiologist before selecting any GLP-1 telehealth program. Following that consultation, programs with physician oversight, access to FDA-approved medications, and clear protocols for medication coordination may be more appropriate than compounded-only telehealth models. No telehealth program substitutes for the clinical coordination a cardiologist review provides for patients with established cardiovascular disease or complex medication regimens.
What is the cheapest GLP-1 telehealth program in 2026?
Promotional pricing for compounded GLP-1 programs has ranged from approximately $133 to $200 per month for compounded semaglutide. Lowest price is not equivalent to lowest risk or best clinical value. FDA-approved Wegovy through NovoCare runs approximately $349/month self-pay; Medicare coverage at a $50 copay begins July 2026 for eligible beneficiaries. The appropriate cost-value calculation depends on insurance status, eligibility for manufacturer savings programs, and individual tolerance for the regulatory environment around compounded medications.
How do I verify a GLP-1 telehealth program is legitimate?
Five verifiable indicators: LegitScript certification; ability to name the specific compounding pharmacy; availability of Certificates of Analysis (sterility, endotoxin, potency); licensed physician or nurse practitioner review with individualized prescribing; and ToS language that accurately matches FAQ or program description claims. Programs that cannot provide these on request warrant caution. The FAQ-to-ToS discrepancy documented for Novi in this review is an example of a term inconsistency every prospective patient should check before enrolling in any program.
Can I switch from a compounded GLP-1 program to a branded medication?
Yes. Branded Wegovy and Zepbound are available through traditional pharmacy networks, manufacturer direct programs, and beginning July 2026, Medicare Part D. A valid prescription from a licensed clinician is required. Dose conversion from compounded to branded formulation may not be 1:1 — confirm the appropriate starting dose with a prescribing clinician at the time of transition.
This comparison is for informational purposes only and does not guarantee eligibility, pricing, prescription access, or results for any reader. Program details change; verify directly with each platform before enrolling. No independent product testing was conducted. This comparison may include affiliate relationships disclosed above. Last reviewed: May 2026.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.